Olleyes and Tobii announce partnership to incorporate advanced eye tracking into VisuALL ETS.
Olleyes, NJ –May 6, 2022 – Olleyes Inc., a medical software company focused on the development of the VisuALL Virtual Reality Platform (VRP) for assessment of visual functions, announced today a partnership with Tobii to incorporate advanced eye tracking features within the VisuALL ETS package.
Based in Stockholm, Sweden, and with 14 offices across four different continents, Tobii is the global leader in eye tracking and pioneer in attention computing. The company pioneered the world's first remote eye tracker over 20 years ago and has remained at the forefront of the R&D and integration of innovative gaze-capturing technology to the present day. Tobii technology will further enhance the capabilities of the Olleyes VisuALL ETS to deliver a variety of ophthalmic tests with superior accuracy via its portable and patient-friendly interface.
"Tobii is proud to enable innovators like Olleyes in its ambition of significantly improving accuracy and efficiency of visual field assessment by automatically analysing the retinal sensitivity in patients with Glaucoma and other visual disorders," said Johan Hellqvist, VP of XR at Tobii. "By incorporating Tobii's leading eye technology like Tobii Ocumen in Olleyes' VisuALL ETS package, we continue to push the boundaries of technology for good."
The Olleyes VisuALL tests collect data by projecting stimuli on specific areas of the retina as a user interacts with the device's software. Users who are unable to focus on the necessary visual cues—or who avert their gaze frequently—may disrupt the analysis and put themselves at risk of reducing the accuracy of the test results. These concerns have previously made gathering ocular information from some patients challenging.
By utilizing Tobii eye tracking, the VisuALL ETS stimulus remains consistent with the same region of the retina regardless of user error. It also vastly increases the precision of the data and improves doctors' ability to confidently diagnose their patients through highly optimized means. This is possible thanks to Olleyes testing algorithms implemented in the new VisuALL model ETS. Advancements made by this new eye tracking technology will allow for even more ocular tests to be integrated into the device, including perimetry scans and ocular motility testing.
“Olleyes is the leading group in the VR market for eyecare. Our VisuALL Virtual Reality Platform (VRP) provides automatic, objective, and standardized visual function tests. Our partnership with Tobii will allow us to increase the accuracy of our technology even more. Tobii Ocumen has helped us quickly develop and deploy our product offerings and is a step forward in automating the remote assessment of visual function,” said Alberto Gonzalez, CEO of Olleyes.
Tobii operates from a position of multifaceted expertise, having also played important roles in developing eye-tracking technology within many application areas, including healthcare, training, education, automotive, and gaming industries. Olleyes anticipates leveraging Tobii's profound domain knowledge and cross-disciplinary experience to make an important stride forward for the VisuALL device, continuing the trend of marrying powerful ophthalmic equipment with optimized office flow via user-friendly technology.
Tobii is the global leader in eye tracking and pioneer of attention computing. We are on a mission to improve the world with technology that understands human attention and intent. Creating tech for a better future, our technologies and solutions apply to areas such as behavioural studies and research, healthcare, education and training, gaming, extended reality, automotive, and many more. Tobii's eye tracking is used by thousands of enterprises, universities, and research institutes around the globe. Headquartered in Sweden, Tobii is listed on Nasdaq Stockholm (TOBII). For more information: www.tobii.com.
Olleyes is a privately held medical software company committed to developing efficient and productive diagnostic technology. Olleyes' life-transforming products are designed for the office and home evaluation of patients with eye diseases like glaucoma, diabetic retinopathy, and age-related macular degeneration.
The company is led by a management team experienced in the development and commercialization of medical devices. Olleyes' strategy is predicated upon efficiency and accessibility to deliver accurate and repeatable visual tests.
For more information on Olleyes, please visit the company's website at www.olleyes.com